Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
08 December 2023 | Story Leonie Bolleurs | Photo Charl Devenish
Thabo Dithebe
When Thabo Dithebe walked across the stage in the Callie Human Centre, a childhood dream came true, despite several difficulties he had to deal with during his studies.

Thabo Dithebe received his Bachelor of Management Leadership (BML) qualification during the University of the Free State’s December graduation ceremonies. His life journey of resilience, adaptability, and a willingness to embrace unexpected opportunities is an inspiring story that needs to be told. 

Born in the farming community of Bothaville, Thabo initially wanted to pursue a career in engineering, and he chose maths, science, and technical subjects in high school. However, a temporary job in retail near home and experiencing the toll of retrenchment redirected his path to sales and marketing and pushed him to apply for a BML in the UFS Business School.

“When I enrolled for the BML, my childhood dream of going to university became a reality. Although the journey was not easy, it was worth pursuing,” says Thabo, who is employed as an area sales manager at Marltons Pet Care.

Balancing studies and responsibilities at home

In addition to managing the pressure of being stretched to the limit in class, Thabo also had to balance his studies with the responsibilities at home – taking care of his sick and disabled daughter.

“Balancing these commitments was always a challenge, but I was fortunate to have a supportive caregiver who understood the needs of children living with disabilities. There were tough times, especially during submission seasons when my daughter would fall ill. In those moments, I had to prioritise her health, temporarily setting aside my studies until she received proper care at the hospital,” he states.

Besides caring for his daughter and being retrenched, he also went through a breakup. Thabo believes that things could have turned out differently if he had stopped imagining and dreaming, because he had every reason to give up. He describes reaching this significant milestone in his life as ‘unreal’. 

He says that he was motivated to persevere, because from the first day he enrolled, he wanted to make his family proud of him. “There were times when I asked myself if I had what it takes to complete the programme. Should I choose not to complete the course, what would I say to my son when life knocks him down, when he sees me giving up? How do I face my mother if I came back defeated? I had good people on my side who wanted me to succeed,” he says.

Ready to take on the next challenge

Having reached this significant milestone in his life, Thabo is ready for the next challenge. “I am hoping to be accepted into the PGDip in Business Administration programme for the 2024 intake,” he says. 

He advises others who face challenges while pursuing their educational goals to understand that their situation is not permanent and that there is strength in adversity. “It is important to celebrate the small victories often and to associate yourself with people who work harder than you,” he adds.

On 7 December 2023, as Thabo walked across the stage, he looked for the face of his mother in the audience – a lady who made several sacrifices to raise him and his five siblings. “I hope that when she saw me, she was very proud of me,” he concludes. 

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept